PL4192882T3 - Leczenie toczniowego zapalenia nerek przeciwciałem przeciwko receptorowi typu i inf anifrolumabem - Google Patents
Leczenie toczniowego zapalenia nerek przeciwciałem przeciwko receptorowi typu i inf anifrolumabemInfo
- Publication number
- PL4192882T3 PL4192882T3 PL22724712.9T PL22724712T PL4192882T3 PL 4192882 T3 PL4192882 T3 PL 4192882T3 PL 22724712 T PL22724712 T PL 22724712T PL 4192882 T3 PL4192882 T3 PL 4192882T3
- Authority
- PL
- Poland
- Prior art keywords
- anifrolumab
- treatment
- type
- receptor antibody
- lupus nephritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rehabilitation Therapy (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178745P | 2021-04-23 | 2021-04-23 | |
| US202163221986P | 2021-07-15 | 2021-07-15 | |
| US202163270091P | 2021-10-21 | 2021-10-21 | |
| PCT/EP2022/060670 WO2022223771A1 (en) | 2021-04-23 | 2022-04-22 | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4192882T3 true PL4192882T3 (pl) | 2025-04-28 |
Family
ID=81750638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22724712.9T PL4192882T3 (pl) | 2021-04-23 | 2022-04-22 | Leczenie toczniowego zapalenia nerek przeciwciałem przeciwko receptorowi typu i inf anifrolumabem |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220348669A1 (pl) |
| EP (2) | EP4192882B1 (pl) |
| JP (1) | JP7746407B2 (pl) |
| KR (1) | KR20240001704A (pl) |
| AU (1) | AU2022260544A1 (pl) |
| BR (1) | BR112023021514A2 (pl) |
| CA (1) | CA3216395A1 (pl) |
| DK (1) | DK4192882T3 (pl) |
| ES (1) | ES3021882T3 (pl) |
| FI (1) | FI4192882T3 (pl) |
| HU (1) | HUE070524T2 (pl) |
| IL (1) | IL307751B2 (pl) |
| PL (1) | PL4192882T3 (pl) |
| PT (1) | PT4192882T (pl) |
| TW (1) | TW202308691A (pl) |
| WO (1) | WO2022223771A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4306541A3 (en) | 2021-04-23 | 2024-03-27 | Astrazeneca AB | Anti-ifnar1 dosing regime for subcutaneous injection |
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| GB202402824D0 (en) * | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662381B2 (en) | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| SI2250279T1 (sl) | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda |
| PL2473636T3 (pl) | 2009-09-03 | 2017-05-31 | Medimmune, Llc | Diagnostyka interferonu typu 1 |
| MX355060B (es) * | 2010-11-17 | 2018-04-03 | Chugai Pharmaceutical Co Ltd | Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea. |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| KR102320059B1 (ko) * | 2012-06-13 | 2021-11-01 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
| KR102669174B1 (ko) * | 2015-08-19 | 2024-06-10 | 아스트라제네카 아베 | 안정한 항-ifnar1 제형 |
| US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| EP4306541A3 (en) * | 2021-04-23 | 2024-03-27 | Astrazeneca AB | Anti-ifnar1 dosing regime for subcutaneous injection |
| CN113278070B (zh) | 2021-04-25 | 2022-06-14 | 福州迈新生物技术开发有限公司 | 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用 |
| CN113621063A (zh) * | 2021-08-02 | 2021-11-09 | 江苏荃信生物医药有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 |
| CN113527490B (zh) * | 2021-07-13 | 2022-03-01 | 江苏荃信生物医药股份有限公司 | 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法 |
-
2022
- 2022-04-22 PT PT227247129T patent/PT4192882T/pt unknown
- 2022-04-22 AU AU2022260544A patent/AU2022260544A1/en active Pending
- 2022-04-22 EP EP22724712.9A patent/EP4192882B1/en active Active
- 2022-04-22 DK DK22724712.9T patent/DK4192882T3/da active
- 2022-04-22 PL PL22724712.9T patent/PL4192882T3/pl unknown
- 2022-04-22 KR KR1020237040114A patent/KR20240001704A/ko active Pending
- 2022-04-22 HU HUE22724712A patent/HUE070524T2/hu unknown
- 2022-04-22 FI FIEP22724712.9T patent/FI4192882T3/fi active
- 2022-04-22 US US17/660,340 patent/US20220348669A1/en active Pending
- 2022-04-22 EP EP25158131.0A patent/EP4595996A3/en active Pending
- 2022-04-22 BR BR112023021514A patent/BR112023021514A2/pt unknown
- 2022-04-22 CA CA3216395A patent/CA3216395A1/en active Pending
- 2022-04-22 ES ES22724712T patent/ES3021882T3/es active Active
- 2022-04-22 TW TW111115513A patent/TW202308691A/zh unknown
- 2022-04-22 JP JP2023564485A patent/JP7746407B2/ja active Active
- 2022-04-22 WO PCT/EP2022/060670 patent/WO2022223771A1/en not_active Ceased
- 2022-04-22 US US18/556,733 patent/US20250002590A1/en active Pending
-
2023
- 2023-10-16 IL IL307751A patent/IL307751B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3021882T3 (en) | 2025-05-27 |
| AU2022260544A9 (en) | 2023-12-07 |
| IL307751A (en) | 2023-12-01 |
| IL307751B2 (en) | 2025-12-01 |
| AU2022260544A1 (en) | 2023-11-30 |
| EP4595996A3 (en) | 2025-12-03 |
| DK4192882T3 (da) | 2025-03-10 |
| HUE070524T2 (hu) | 2025-06-28 |
| US20220348669A1 (en) | 2022-11-03 |
| JP2024518735A (ja) | 2024-05-02 |
| KR20240001704A (ko) | 2024-01-03 |
| WO2022223771A1 (en) | 2022-10-27 |
| BR112023021514A2 (pt) | 2023-12-19 |
| TW202308691A (zh) | 2023-03-01 |
| CA3216395A1 (en) | 2022-10-27 |
| PT4192882T (pt) | 2025-05-02 |
| EP4192882A1 (en) | 2023-06-14 |
| EP4192882B1 (en) | 2025-02-19 |
| IL307751B1 (en) | 2025-08-01 |
| EP4595996A2 (en) | 2025-08-06 |
| US20250002590A1 (en) | 2025-01-02 |
| JP7746407B2 (ja) | 2025-09-30 |
| FI4192882T3 (fi) | 2025-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL307751B2 (en) | Treatment of renal lupus using the anti-inf receptor type I antibody aniprolumab | |
| MX2021004270A (es) | Anticuerpos estabilizadores de trem2. | |
| JOP20210194A1 (ar) | مستقبلات المستضدات الخيمرية لـ gprc5d وخلايا تعبر عنها | |
| SG11202106593UA (en) | Anti-transferrin receptor antibodies and uses thereof | |
| SG11202107976SA (en) | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) | |
| IL258862A (en) | Derivatives Ann .- [2- (1-Benzylphipridine-4-yl) ethyl] -4- (Pirazine-2-yl) -pipridine-1-carboxamide and compounds related as muscarinic receptor 4 antagonists for the treatment of neurological diseases | |
| PH12020551443A1 (en) | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease | |
| IL291665A (en) | Inhibitors of receptor interaction with protein kinase i for the treatment of disease | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| EA202091803A1 (ru) | Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| EP3907239A4 (en) | Monoclonal antibodies against the beta chain region of human trbv9 | |
| EP4065565A4 (en) | RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS FOR THE TREATMENT OF DISEASE | |
| CL2007002958A1 (es) | Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr | |
| SG11202011296VA (en) | Compositions and methods for the treatment of parkinson's disease | |
| EP3734268A4 (en) | SIMPLIFIED METHOD OF QUANTIFYING MONOCLONAL ANTIBODIES | |
| IL290852A (en) | Treatment of liver disease or disorder involving actrii receptor antagonists | |
| EP3833435A4 (en) | DETERMINATION OF PARKINSON'S DISEASE | |
| IL304249A (en) | Antibodies to human complement 5a receptor 1 and methods of using them | |
| EP3813823A4 (en) | Compositions and methods for agonizing the cb2 receptor | |
| IL285937A (en) | Synthesis of 4-amino-5-methyl-h1-pyridin-2(h1)-one (intermediate compound for the synthesis of the antagonist mr) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using compound The intermediate 2-chloro-5-methyl-4-pyridineamine | |
| ZA202101489B (en) | Compositions and methods for the treatment of parkinson's disease | |
| EP3802795A4 (en) | Kits, compositions and methods for myeloid-derived suppressor cell enrichment | |
| MA49883A (fr) | Composés bicycliques aptes à se lier au récepteur de mélanocortine 4 | |
| IL308045A (en) | Treatment of lupus nephritis using antibuffer antibodies | |
| EP3463372A4 (en) | CONDENSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES |